B. Riley lowered the firm’s price target on PDS Biotechnology (PDSB) to $5 from $7 and keeps a Buy rating on the shares. The firm cites PDS01 f antibody drug conjugate triplet revenue contribution push out given the company’s heightened focus on securing Versamune HPV doublet path to market for the target cut.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PDSB:
- PDS Biotechnology Director Sir Richard Sykes Retires
- PDS Biotech’s Earnings Call Highlights: Clinical Progress Amid Funding Challenges
- PDS Biotechnology Advances Cancer Immunotherapy Trials
- PDS Biotechnology price target lowered to $13 from $21 at H.C. Wainwright
- Options Volatility and Implied Earnings Moves Today, March 27, 2025